According to TipRanks, Jones CFA is a 5-star analyst with an average return of 17.3% and a 52.99% success rate. Jones CFA covers the Technology sector, focusing on stocks such as Zillow Group Class A, Opendoor Technologies, and Offerpad Solutions.
Currently, the analyst consensus on Expedia is a Moderate Buy with an average price target of $141.24, representing a 37.77% upside. In a report released on August 5, Mizuho Securities also maintained a Hold rating on the stock with a $132.00 price target.
EXPE market cap is currently $16.11B and has a P/E ratio of 51.15.
Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EXPE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Expedia Group, Inc. is an online travel company, which engages in the provision of travel products and services to leisure and corporate travellers. It operates through the following business segments: Core Online Travel Agency(OTA), Trivago, Vrbo, and Egencia. The Core OTA segment offers full range of travel and advertising services to worldwide customers through a variety of brands including: Expedia.com and Hotels.com. The Trivago segment involves in sending referrals to online travel companies and travel service providers from its hotel metasearch websites. The Vrbo segment operates an online marketplace for the alternative accommodations industry. The Egencia segment manages travel services to corporate customers worldwide. The company was founded in 1994 and is headquartered in Seattle, WA.
Read More on EXPE:
- JMP Securities Remains a Buy on Owl Rock Capital (ORCC)
- Century Casinos (CNTY) Receives a Buy from JMP Securities
- Western Digital Stock: Current Headwinds Present an Attractive Opportunity
- JMP Securities Remains a Buy on Compugen (CGEN)
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (IOVA), Cellectis SA (CLLS) and Orthofix (OFIX)